Literature DB >> 25037601

Cost-effectiveness of training rural providers to identify and treat patients at risk for fragility fractures.

S D Nelson1, R E Nelson, G W Cannon, P Lawrence, M J Battistone, M Grotzke, Y Rosenblum, J LaFleur.   

Abstract

UNLABELLED: This is a cost-effectiveness analysis of training rural providers to identify and treat osteoporosis. Results showed a slight cost savings, increase in life years, increase in treatment rates, and decrease in fracture incidence. However, the results were sensitive to small differences in effectiveness, being cost-effective in 70 % of simulations during probabilistic sensitivity analysis.
INTRODUCTION: We evaluated the cost-effectiveness of training rural providers to identify and treat veterans at risk for fragility fractures relative to referring these patients to an urban medical center for specialist care. The model evaluated the impact of training on patient life years, quality-adjusted life years (QALYs), treatment rates, fracture incidence, and costs from the perspective of the Department of Veterans Affairs.
METHODS: We constructed a Markov microsimulation model to compare costs and outcomes of a hypothetical cohort of veterans seen by rural providers. Parameter estimates were derived from previously published studies, and we conducted one-way and probabilistic sensitivity analyses on the parameter inputs.
RESULTS: Base-case analysis showed that training resulted in no additional costs and an extra 0.083 life years (0.054 QALYs). Our model projected that as a result of training, more patients with osteoporosis would receive treatment (81.3 vs. 12.2 %), and all patients would have a lower incidence of fractures per 1,000 patient years (hip, 1.628 vs. 1.913; clinical vertebral, 0.566 vs. 1.037) when seen by a trained provider compared to an untrained provider. Results remained consistent in one-way sensitivity analysis and in probabilistic sensitivity analyses, training rural providers was cost-effective (less than $50,000/QALY) in 70 % of the simulations.
CONCLUSIONS: Training rural providers to identify and treat veterans at risk for fragility fractures has a potential to be cost-effective, but the results are sensitive to small differences in effectiveness. It appears that provider education alone is not enough to make a significant difference in fragility fracture rates among veterans.

Entities:  

Mesh:

Year:  2014        PMID: 25037601     DOI: 10.1007/s00198-014-2815-1

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  20 in total

Review 1.  Why don't physicians follow clinical practice guidelines? A framework for improvement.

Authors:  M D Cabana; C S Rand; N R Powe; A W Wu; M H Wilson; P A Abboud; H R Rubin
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

Review 2.  Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women.

Authors:  Anna M Sawka; Alexandra Papaioannou; Jonathan D Adachi; Amiram Gafni; David A Hanley; Lehana Thabane
Journal:  BMC Musculoskelet Disord       Date:  2005-07-11       Impact factor: 2.362

3.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

4.  State of infection prevention in US hospitals enrolled in the National Health and Safety Network.

Authors:  Patricia W Stone; Monika Pogorzelska-Maziarz; Carolyn T A Herzig; Lindsey M Weiner; E Yoko Furuya; Andrew Dick; Elaine Larson
Journal:  Am J Infect Control       Date:  2014-02       Impact factor: 2.918

5.  The effect of increased travel reimbursement rates on health care utilization in the VA.

Authors:  Richard E Nelson; Bret Hicken; Alan West; Randall Rupper
Journal:  J Rural Health       Date:  2011-08-24       Impact factor: 4.333

6.  Using the osteoporosis self-assessment tool for referring older men for bone densitometry: a decision analysis.

Authors:  Kouta Ito; James P Hollenberg; Mary E Charlson
Journal:  J Am Geriatr Soc       Date:  2009-02       Impact factor: 5.562

7.  Cost effectiveness of training rural providers to perform joint injections.

Authors:  Richard E Nelson; Michael J Battistone; William D Ashworth; Andrea M Barker; Marissa Grotzke; Timothy A Huhtala; Joanne Lafleur; Robert Z Tashjian; Grant W Cannon
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-04       Impact factor: 4.794

8.  Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.

Authors:  John T Schousboe; Brent C Taylor; Howard A Fink; Robert L Kane; Steven R Cummings; Eric S Orwoll; L Joseph Melton; Douglas C Bauer; Kristine E Ensrud
Journal:  JAMA       Date:  2007-08-08       Impact factor: 56.272

Review 9.  Osteoporosis in men.

Authors:  Luigi Gennari; John P Bilezikian
Journal:  Endocrinol Metab Clin North Am       Date:  2007-06       Impact factor: 4.741

10.  Updated fracture incidence rates for the US version of FRAX.

Authors:  B Ettinger; D M Black; B Dawson-Hughes; A R Pressman; L J Melton
Journal:  Osteoporos Int       Date:  2009-08-25       Impact factor: 4.507

View more
  3 in total

1.  "Mini-Residency" in Musculoskeletal Care: a National Continuing Professional Development Program for Primary Care Providers.

Authors:  Michael J Battistone; Andrea M Barker; Marissa P Grotzke; J Peter Beck; Phillip Lawrence; Grant W Cannon
Journal:  J Gen Intern Med       Date:  2016-06-27       Impact factor: 5.128

2.  Effectiveness of an Interprofessional and Multidisciplinary Musculoskeletal Training Program.

Authors:  Michael J Battistone; Andrea M Barker; Marissa P Grotzke; J Peter Beck; Jeffery T Berdan; Jorie M Butler; Caroline K Milne; Tim Huhtala; Grant W Cannon
Journal:  J Grad Med Educ       Date:  2016-07

3.  Calculating the Baseline Incidence in Patients Without Risk Factors: A Strategy for Economic Evaluation.

Authors:  Scott D Nelson; Daniel Malone; Joanne Lafleur
Journal:  Pharmacoeconomics       Date:  2015-09       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.